Breast Cancer Female Clinical Trial
— Believe@BCOfficial title:
A Convergent Parallel Mixed-methods Feasibility Study of the Bone@BC App Version 3.0 to Investigate Feasibility and Satisfaction
Introduction Due to improvements in diagnostics and treatments, the 5-year survival for patients with breast cancer is 80-90% after initial diagnosis. During treatments, patients typically have consultations weekly and then gradually reduce to annual visits. During this transition from hospital-based care to health self-management, the breast cancer survivors are encouraged to e.g. exercise because of accumulating evidence for the efficacy of exercise training in cancer survivorship, and in the majority of cases, adhere to endocrine treatments to reduce the risk of breast cancer recurrence. Design and methods The study is a one-arm convergent parallel mixed-methods feasibility intervention study. The quantitative data will be the use of the Bone@bc app (intervention) and questionnaires (n=50) and the Qualitative data will be semi-structured interviews (n= 15 - 20)
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | October 30, 2024 |
Est. primary completion date | October 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 50 Years to 70 Years |
Eligibility | Inclusion Criteria: - Postmenopausal women - Age 50-70 years - Danish speaking - Diagnosed with EBC, stage I-III - Eligible to receive (neo-) adjuvant chemotherapy or adjuvant treatments - Access to an E-mail address - Access to smart mobile electronic devices connected to the internet - Willingness to have the app installed on the smart mobile electronic devices - Ability to work with the app Exclusion Criteria: - Prior malignancy - Pre-existing type 2 diabetes or other metabolic diseases - Withdrawn or not given a consent form |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The System Usability Scale (SUS) | a self-administrated questionnaire with 10 items with five response options for respondents; from Strongly agree to Strongly disagree. A SUS score above a 68 would be considered above average and anything below 68 is below average. | Week 12 | |
Primary | Feasibility parameters as adherence, acceptability, response rate, representativeness, recruitment rate, and satisfaction | Semi-structured interviews | Week 12 | |
Primary | Bone@BC app | Patient-reported outcome(s) from the app on the questions provided daily on Health-Related Quality of Life, late side-effects, symptoms and concerns perspectives, and level of Physical Activity in the app Bone@BC). The daily questions will be from the Eortc Library and will be analysed in percentages. | From baseline and to week 12 | |
Secondary | Changes in symptoms of depression and anxiety measured by Hospital Anxiety and Depression Scale | The Hospital Anxiety and Depression scale is a 14-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression. | baseline (0 months) and week 12 | |
Secondary | Changes in Quality of life measured by the European Organization for Research and Treatment of Cancer Quality of Life | Health-related quality of life scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. |
baseline (0 months) and week 12 | |
Secondary | Changes in self-efficacy measured by Self-efficacy for managing chronic disease 6-item scale (SES6G) | The Self-efficacy for managing chronic disease 6 item scale is a 6 item scale. Scoring for each item ranges from zero to ten. A high scale score represents a high self-efficacy. | Week 4, week 8 end week 12 | |
Secondary | Changes in patient empowerment measured by The Health Education Impact Questionnaire. | he Health Education Impact Questionnaire i a 42 items questionnaire with a 4 point response scale (strongly disagree, disagree, agree and strongly agree). Higher values in the Health Education Impact Questionnaire scales indicate better status, except for Emotional distress, where higher values indicate higher distress. | baseline (0 months) and week 12 | |
Secondary | Changes in in app user measured by Open source web analytics application Matomo Analytics | In-app user analytics will be collected to track user behavior such as the number of app sessions the user have measured by numbers (quantity). Length of app sessions measured by time (hours and sec.). Frequency of use measured in numbers (quantity). Data on when the app was first opened measured as the specific site. Geographic place measured as country. How many pages the users use measured as numbers (quantity). How long time the users spend on the pages measured as time (hours and sec.). Bounce rate measured as numbers (quantity). Returning for the first time measured as numbers (quantity). |
week 4, week 8 and week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03080623 -
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
|
||
Completed |
NCT05527769 -
Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
|
||
Completed |
NCT03004534 -
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
|
Early Phase 1 | |
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Active, not recruiting |
NCT06277141 -
The Vitality Mammography Messaging Study
|
N/A | |
Completed |
NCT03555227 -
USG PECS vs LIA for Breast Cancer Surgery
|
N/A | |
Completed |
NCT03270111 -
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
|
N/A | |
Active, not recruiting |
NCT03917082 -
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05561842 -
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
|
||
Completed |
NCT04554056 -
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06351332 -
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03127995 -
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
|
N/A | |
Active, not recruiting |
NCT02237469 -
Prone Breast Radiotherapy Treatment Planning Observational Study
|
||
Completed |
NCT01204125 -
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04565054 -
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
|
Phase 3 | |
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT06058936 -
Exercises Using Virtual Reality on Cancer Patients
|
N/A | |
Completed |
NCT03470935 -
Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
|
||
Recruiting |
NCT06025604 -
ACTIVPROSEIN : Professional Activity After Breast Cancer
|